Keros Therapeutics, Inc. presented additional clinical data from its Phase 1 clinical trial of KER-065 in healthy male volunteers at the American Society of Bone and Mineral Research 2025 Annual Meeting.
The data highlights the broad therapeutic potential of KER-065, especially in Duchenne muscular dystrophy.
The Phase 1 trial demonstrated positive results in bone biomarkers and whole body bone mineral density improvements.
Therapeutic Potential of KER-065
The Phase 1 trial showcased the robust bone anabolic activity and potential in treating disorders related to TGF-ß signaling dysfunction.
Safety and Tolerability
Treatment with KER-065 was generally well-tolerated with no dose-limiting toxicities or serious adverse events reported.
Bone Biomarkers Improvement
Results showed increased bone formation, reduced bone resorption, and improvements in bone mineral density, suggesting positive effects on bone health.
Product Description
KER-065 is a novel ligand trap targeting myostatin and activin A to enhance muscle regeneration, increase muscle size and strength, and improve bone strength.
- The clinical trial data supports the development of KER-065 in Duchenne Muscular Dystrophy and other bone disorders.
- The positive outcomes in bone biomarkers and bone mineral density improvements indicate the potential for KER-065 to address the challenges associated with progressive muscle weakness and chronic corticosteroid use in Duchenne Muscular Dystrophy.
The additional clinical data presented by Keros Therapeutics reinforces the promising therapeutic potential of KER-065 in addressing bone disorders and neuromuscular diseases like Duchenne Muscular Dystrophy. The results from the Phase 1 trial provide strong support for the continued development of this novel therapeutic approach.